RESEARCH MONOGRAPH · KDC-MN-046

Donepezil

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

83/100

The cleanest selective AChE inhibitor available, more useful as a research tool than as the drug

Donepezil is the workhorse selective AChE inhibitor, and honestly thats both the headline and the limitation. Eisai brought it through development in the 90s (Sugimoto's group did the original piperidine medicinal chemistry), got it approved as Aricept, and it became the dominant Alzheimer's drug in most of the world for the better part of two decades. So the human safety database is enormous, the pharmacology is fully characterized, and the molecule itself is just very well-behaved.

What makes it a useful research tool is the selectivity profile. Roughly 1000-fold selectivity over butyrylcholinesterase, clean CYP profile, long half-life (around 70 hours in humans), and minimal off-target activity at standard concentrations. So if you want to ask the question "what happens when I inhibit central AChE specifically and let everything else alone," donepezil is the molecule.

The clinical story is more mixed than the prescribing pattern suggests. The cognitive endpoint improvements in Alzheimer trials are real but modest, the effect tends to plateau by 6-12 months, and the disease-modification question (does it actually slow progression?) was answered no decades ago. Symptomatic enhancement, not disease modification. The field has known this for a while.

What we like: as clean an AChE probe as exists, predictable PK, the safety database is enormous, and the long half-life makes dosing schedules forgiving in research models.

What we dont like: the cholinergic side effect profile is real (nausea, vivid dreams, bradycardia), it does nothing for the underlying neurodegeneration, and the field has somewhat moved past it as the primary therapeutic strategy in dementia. But none of that matters for using it as a research tool, where the cleanness is exactly what you want.

Sourcing is essentially trivial. Generic for years now, pharmacopoeia-grade material is widely available, HPLC validation is routine, and stability is excellent. Storage is forgiving.

For research where you need to ask cholinergic enhancement questions cleanly, donepezil is the right starting point. The richer pharmacology compounds (galantamine, rivastigmine, huperzine) all have their uses, but for the simple experiment, this is it.

Evidence: 95
Mechanism: 90
Reliability: 88
Safety: 75
Sourcing: 90
Value: 80
Signal: 65
Staying power: 80

Plain-language summary Intrigue 75 / 100

Donepezil, sold as Aricept, is the most prescribed acetylcholinesterase inhibitor for Alzheimer disease. It selectively raises brain acetylcholine to compensate for cholinergic neuron loss in dementia. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Selective acetylcholinesterase inhibitor

A piperidine-class selective reversible acetylcholinesterase inhibitor, FDA-approved as Aricept for Alzheimer disease, with the largest clinical evidence base of the AChE inhibitor class.

Abstract

Donepezil (Aricept; (R/S)-2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-2,3-dihydro-1H-inden-1-one hydrochloride; CAS 120014-06-4; molecular formula C24H29NO3; molecular weight 379.49) is a piperidine-class selective reversible acetylcholinesterase inhibitor developed by Eisai and approved by the FDA in 1996 for mild, moderate, and severe Alzheimer disease. The compound has the highest AChE selectivity (over 1000-fold versus butyrylcholinesterase) of the marketed AChE inhibitors and a long plasma half-life (70 hours). Mechanism is selective AChE inhibition without significant secondary activities at nicotinic receptors or other targets. The clinical evidence base in Alzheimer disease is extensive; multiple Phase 3 trials demonstrate small but consistent improvements in cognitive endpoint measures (ADAS-cog, MMSE) and global functional status. The compound is also approved for vascular dementia and Parkinson disease dementia in some jurisdictions. Pharmacokinetics: oral bioavailability essentially complete; metabolism is hepatic via CYP2D6 and CYP3A4 with minor active metabolites. Reported research dose ranges in the literature span 5 to 23 mg; the 23 mg formulation was approved in 2010 for severe Alzheimer disease. Schedule status: prescription-only but not federally scheduled.

Mechanism of action

Selective reversible AChE inhibitor with >1000-fold selectivity over BChE. No significant nAChR or NMDA activity.

Reported research dose ranges

Reported research dose ranges in the literature span 5 to 23 mg.

References

Sugimoto H, et al. Donepezil hydrochloride: a review of its use in Alzheimer's disease. Drugs Aging 2003.
Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 2018.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, reported research dose ranges, sourcing and quality verification, reconstitution and handling, stack interaction considerations, and a curated reference list. Available as a research-use-only PDF download.

KDC-MN-046

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Donepezil

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs